© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Arcutis Biotherapeutics, Inc. (ARQT) stock declined over -2.59%, trading at $20.69 on NASDAQ, down from the previous close of $21.24. The stock opened at $21.30, fluctuating between $20.27 and $21.56 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| May 12, 2026 | 21.30 | 21.56 | 20.27 | 20.69 | 2.31M |
| May 11, 2026 | 21.32 | 21.72 | 20.94 | 21.24 | 3.26M |
| May 08, 2026 | 20.71 | 21.36 | 20.26 | 21.17 | 2.7M |
| May 07, 2026 | 22.82 | 23.77 | 20.19 | 20.66 | 6.69M |
| May 06, 2026 | 23.81 | 24.27 | 23.25 | 24.17 | 1.37M |
| May 05, 2026 | 23.72 | 24.03 | 23.15 | 23.42 | 850.23K |
| May 04, 2026 | 23.15 | 23.95 | 23.13 | 23.49 | 1.27M |
| Apr 30, 2026 | 22.58 | 23.35 | 22.47 | 23.22 | 1.36M |
| Apr 29, 2026 | 22.86 | 23.14 | 22.13 | 22.37 | 1.11M |
| Apr 28, 2026 | 23.66 | 24.00 | 22.93 | 23.29 | 995.68K |
| Apr 27, 2026 | 23.32 | 24.15 | 23.15 | 23.42 | 812.26K |
| Apr 23, 2026 | 23.75 | 23.87 | 22.45 | 22.86 | 1.06M |
| Apr 22, 2026 | 23.60 | 23.91 | 23.44 | 23.75 | 805.73K |
| Apr 21, 2026 | 24.27 | 24.27 | 23.27 | 23.40 | 736.47K |
| Apr 20, 2026 | 24.43 | 24.50 | 23.88 | 24.47 | 875.86K |
| Apr 17, 2026 | 24.76 | 24.80 | 24.24 | 24.53 | 1.16M |
| Apr 16, 2026 | 24.56 | 24.62 | 23.68 | 24.19 | 900.66K |
| Apr 14, 2026 | 24.30 | 25.47 | 24.22 | 25.09 | 1.6M |
| Apr 13, 2026 | 23.87 | 24.51 | 23.82 | 24.12 | 812.5K |
| Apr 10, 2026 | 24.47 | 24.54 | 23.59 | 24.21 | 894.69K |
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
| Employees | 342 |
| Beta | 1.77 |
| Sales or Revenue | $59.61M |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |